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A B S T R A C T   
The effect of migalastat on long-term renal outcomes in enzyme replacement therapy (ERT)–naive and ERT- 
experienced patients with Fabry disease is not well defined. An integrated posthoc analysis of the phase 3 
clinical trials and open-label extension studies was conducted to evaluate long-term changes in renal function in 
patients with Fabry disease and amenable GLA variants who were treated with migalastat for ≥2 years during 
these studies. The analysis included ERT-naive (n = 36 [23 females]; mean age 45 years; mean baseline estimated 
glomerular filtration rate (eGFR), 91.4 mL/min/mL/1.73 m2) and ERT-experienced (n = 42 [24 females]; mean 
age, 50 years; mean baseline eGFR, 89.2 mL/min/1.73m2) patients with amenable variants who received 
migalastat 123 mg every other day for ≥2 years. The annualized rate of change from baseline to last observation 
in estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation 
(eGFRCKD-EPI) was calculated by both simple linear regression and a random coefficient model. In ERT-naive 
patients, mean annualized rates of change from baseline in eGFRCKD-EPI were − 1.6 mL/min/1.73 m2 overall 
and − 1.8 mL/min/1.73 m2 and − 1.4 mL/min/1.73 m2 in male and female patients, respectively, as estimated 
by simple linear regression. In ERT-experienced patients, mean annualized rates of change from baseline in 
eGFRCKD-EPI were − 1.6 mL/min/1.73 m2 overall and − 2.6 mL/min/1.73 m2 and − 0.8 mL/min/1.73 m2 in male 
and female patients, respectively. Mean annualized rate of change in eGFRCKD-EPI in ERT-naive patients with the 
classic phenotype (defined by white blood cell alpha galactosidase A [α-Gal A] activity of <3% of normal and 
multiorgan system involvement) was − 1.7 mL/min/1.73 m2. When calculated using the random coefficient 
model, which adjusted for sex, age, and baseline renal function, the annualized eGFRCKD-EPI change was minimal 
(mean: − 0.1 and 0.1 mL/min/1.73 m2 in ERT-naive and ERT-experienced patients, respectively). In conclusion, 
patients with Fabry disease and amenable GLA variants receiving long-term migalastat treatment (≤8.6 years) 
maintained renal function irrespective of treatment status, sex, or phenotype.  
Abbreviations: α-Gal A, α-galactosidase A; Gb3, globotriaosylceramide; eGFRCKD-EPI, estimated glomerular filtration rate using the Chronic Kidney Disease 
Epidemiology Collaboration equation; GLP-HEK, Good Laboratory Practice-validated human embryonic kidney; LVMi, left ventricular mass index; Q1, quartile 1; Q3, 
quartile 3; RI, renin inhibitor. 
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1. Introduction 
Fabry disease is a rare, multisystemic disorder caused by pathogenic 
GLA gene variants that result in functional deficiency of lysosomal 
enzyme α-galactosidase A (α-Gal A) and accumulation of globo-
triaosylceramide (Gb3) throughout the body [1,2]. 
In the kidney, glycosphingolipids accumulate in multiple kidney cell 
types, such as podocytes, endothelial cells, and tubular epithelial cells, 
causing proteinuria and a decline in glomerular filtration rate (GFR) [3]. 
Furthermore, the accumulation of Gb3 activates inflammatory and 
profibrotic processes that subsequently lead to glomerular injury [4,5]. 
Fabry disease is X-linked, and hemizygous males typically experience 
the most severe manifestations; however, heterozygous females can 
develop complications in major organs [1]. Renal manifestations are a 
significant cause of mortality and morbidity in Fabry disease [6,7], with 
renal disease being reported as the third most common cause of death 
after cardiac and cerebrovascular disease based on registry data [7]. 
Furthermore, decreased renal function and kidney failure have been 
associated with cardiovascular events and stroke, suggesting that renal 
















































































Fig. 1. Patient flow in phase 3 studies of migalastat. 
aThe AT1001–041 study also included 12 amenable patients from phase 2 studies. 
bThe AT1001–042 study also enrolled 1 patient from a phase 2 study, for a total of 84 patients, including 1 patient who had a nonamenable GLA variant. 
cOne patient discontinued due to an adverse event, 3 patients met protocol-defined stopping criteria (ie, estimated glomerular filtration rate < 30 mL/min/1.73 m2), 
1 patient was lost to follow-up, 4 patients discontinued per physician decision, and 2 patients chose to withdraw. 
dDuration of the treatment varied among patients. Patients completed the study when they switched to commercial migalastat or had access to migalastat through an 
alternate source. ERT, enzyme replacement therapy; QOD, every other day. 
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Current treatments for Fabry disease include enzyme replacement 
therapy (ERT) with recombinant human α-Gal A and the oral pharma-
cological chaperone migalastat [10–12]. As a small molecule pharma-
cological chaperone, migalastat binds to and stabilizes amenable mutant 
forms of α-Gal A in the endoplasmic reticulum, facilitating trafficking of 
α-Gal A to lysosomes and restoring endogenous enzyme activity [13,14]. 
Migalastat 123 mg every other day is approved for the treatment of 
Fabry disease in adult patients in the United States and in patients aged 
≥16 years in the European Union who have an amenable GLA variant. 
In phase 3 clinical trials, migalastat demonstrated efficacy in 
reducing Gb3 in diverse renal cell types and in stabilizing renal function 
[15–17]. ERT-naive patients demonstrated stable renal function for ≤2 
years in the double-blind, placebo-controlled study FACETS, as calcu-
lated by simple linear regression [15]. In the open-label, active- 
controlled ATTRACT study, ERT-experienced patients who switched to 
migalastat experienced an annualized rate of change in GFR comparable 
to that of patients who continued ERT [16]. In ERT-naive patients, the 
mean annualized rate of change from baseline to month 24 was − 0.3 
mL/min/1.73 m2 with migalastat [15]. In ERT-experienced patients, the 
mean annualized rate of change in estimated glomerular filtration rate 
(eGFR) from baseline to month 18 was − 0.4 mL/min/1.73 m2 after 
switching to migalastat and − 1.0 mL/min/1.73 m2 in patients 
continuing ERT [16]. 
Studies are ongoing to evaluate long-term renal outcomes in ERT- 
naive and ERT-experienced patients treated with migalastat. Here, a 
post hoc analysis was conducted to evaluate long-term changes in renal 
function in 78 patients with Fabry disease and amenable GLA variants 
who were treated with migalastat for ≥2 years in the phase 3 FACETS 
and ATTRACT trials and long-term open-label extension (OLE) studies. 
2. Materials and methods 
2.1. Design 
ERT-naive and ERT-experienced patients enrolled in the phase 3 
FACETS (AT1001–011; NCT00925301) or ATTRACT (AT1001–012; 
NCT01218659) clinical trials received migalastat 123 mg every other 
day for ≥2 years; details of these studies have been described previously 
[15,16]. Patients completing FACETS or ATTRACT were also allowed to 
enter an additional OLE study of ≤5 years (AT1001–041 
[NCT01458119] and/or AT1001–042 [NCT02194985]). 
We performed a post hoc analysis in which data collected during 
FACETS, ATTRACT, and the subsequent 5-year OLE studies 
(AT1001–041 and/or AT1001–042) (Fig. 1) were integrated across 
studies. The data cutoff date for the ongoing AT1001–042 study was 
March 11, 2020. 
2.2. Participants 
Selection criteria for patients enrolled in the FACETS and ATTRACT 
studies have been previously published [15,16]. Briefly, patients were 
ERT-naive (FACETS; never received ERT or had not received ERT for ≥6 
months) or ERT-experienced (ATTRACT; initiated ERT ≥ 12 months 
before study entry); aged 16–74 years; had genetically confirmed Fabry 
disease; and had GLA variants that met the amenability criteria. Patients 
had an eGFR of ≥30 mL/min/1.73 m2 at enrollment, and those taking 
angiotensin-converting-enzyme inhibitors and/or angiotensin II recep-
tor blockers had to be on a stable dose for ≥4 weeks before the screening 
visit [15,16]. This post hoc analysis included all patients who received 
migalastat for ≥2 years and had migalastat-amenable GLA variants 
based on results from the good laboratory practice-validated assay using 
human embryonic kidney 293 cells (GLP-HEK assay) [18]. 
2.3. Study endpoints and assessments 
Serum creatinine values were used to calculate the estimated 
glomerular filtration rate using the Chronic Kidney Disease Epidemi-
ology Collaboration equation (eGFRCKD-EPI) [19]. eGFRCKD-EPI was 
determined at baseline and every 6 months through to the completion of 
each study, and annualized changes in eGFRCKD-EPI were calculated. 
2.4. Statistical analyses 
The annualized rate of change in eGFRCKD-EPI was calculated with 
two methods: by the slope of simple linear regression based on observed 
values and assessment times [15] and by a random coefficient model 
[20]. The simple linear regression was calculated individually for each 
patient using their longitudinal data. The random coefficient model 
comprised a mixed model that included eGFR as the dependent variable 
and study visit as a main effect, and the rate of eGFR decline was 
adjusted for the following baseline factors: sex, age, baseline eGFRCKD- 
EPI, baseline proteinuria, and time from Fabry diagnosis. Random co-
efficients were used for the intercept and visit. The beginning of miga-
lastat treatment was the baseline and corresponded to month 6 of 
FACETS for patients in the placebo arm and month 18 of ATTRACT for 
patients in the ERT arm. One model was fitted on all data which resulted 
in obtaining a slope for each patient adjusted for the covariates. Then the 
slopes were grouped by sex, baseline eGFRCKD-EPI (>30 to <60, 60–90, 
and > 90 mL/min/1.73 m2), baseline urine protein (< 300, 300–1000, 
and > 1000 mg/24 h). For ERT-naive patients, the slope was also 
grouped by phenotype (male patients with the classic phenotype vs 
others). ERT-naive male patients were classified as having the classic 
phenotype if they had residual white blood cell α-Gal A activity of <3% 
of normal and multiorgan system involvement at baseline, defined as 
involvement of ≥2 of the following organ systems: renal, cardiac, central 
nervous system, peripheral nervous system, and gastrointestinal tract 
(Table A.1) [21]. The classification of “Other” included ERT-naive male 
patients who did not meet the above criteria and all ERT-naive female 
patients [21]. ERT-experienced male patients were not evaluated by 
phenotype because their baseline white blood cell α-Gal A activity may 
have been confounded by previous ERT. Instead, we analyzed a subset of 
ERT-experienced male patients who had multiorgan involvement at 
baseline. 
Descriptive statistics including mean, standard deviation (SD), me-
dian, range, and percent of total were used for efficacy analyses. 
2.5. Ethics 
FACETS, ATTRACT, AT1001–041, and AT1001–042 were designed 
and monitored in accordance with the ethical principles of Good Clinical 
Practice and the Declaration of Helsinki. Clinical protocols for these 
studies were reviewed and approved by the appropriate Independent 
Ethics Committee/Institutional Review Board at each study site. All 
patients provided written informed consent prior to initiation of the 
study. 
3. Results 
3.1. Demographics and baseline characteristics of the integrated analysis 
population 
Demographic characteristics of the 78 patients who had ≥2 years of 
migalastat treatment are shown in Table 1. Of these, 36 were ERT-naive 
(23 females), and 42 were ERT-experienced (24 females). The mean (SD) 
age of patients at treatment initiation was 45.1 (10.5) years in the ERT- 
naive group and 50.1 (13.8) years in the ERT-experienced group. The 
mean (SD) time since Fabry diagnosis was 7.4 (8.0) years in ERT-naive 
patients and 12.6 (12.4) years in ERT-experienced patients. Overall, 
78% of patients had multiorgan involvement (81% of ERT-naive patients 
and 76% of ERT-experienced patients). In particular, male patients with 
the classic phenotype comprised 27.8% of the ERT-naive group and male 
patients with multiorgan involvement made up 35.7% of the ERT- 
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experienced group. The median (range) migalastat treatment duration 
was 7.0 (2.0–8.6) years and 5.1 (2.1–7.2) years for ERT-naive and ERT- 
experienced patients, respectively. 
3.2. Effects on renal function 
During long-term follow-up, renal function was generally stable in 
both ERT-naive and ERT-experienced patients and in both male and 
female patients (Table 2). Using simple linear regression, the mean (SD) 
annualized rates of change in eGFRCKD-EPI were − 1.6 (3.1) mL/min/ 
1.73 m2 and − 1.6 (3.6) mL/min/1.73 m2 in ERT-naive and ERT- 
experienced patients, respectively. eGFRCKD-EPI over time and annual-
ized rate of change in eGFRCKD-EPI in individual patients are shown in 
Fig. 2 and Fig. A.1A, respectively. Using the random coefficient model, 
which adjusted for age, sex, baseline renal function, and time since 
Fabry diagnosis, the mean (SD) annualized rates of change in eGFRCKD- 
EPI were − 0.1 (1.8) mL/min/1.73 m2 and 0.1 (1.7) mL/min/1.73 m2 in 
ERT-naive and ERT-experienced patients, respectively. When patients 
were analyzed by sex, the mean annualized rates of change in eGFRCKD- 
EPI were − 0.5 mL/min/1.73 m2 in (ERT-naive) and − 0.4 mL/min/1.73 
m2 in (ERT-experienced) in males, and 0.1 mL/min/1.73 m2 in (ERT- 
naive) and 0.5 mL/min/1.73 m2 (ERT-experienced) in females 
(Table A.2). 
eGFRCKD-EPI, estimated glomerular filtration rate using the Chronic 
Kidney Disease Epidemiology Collaboration equation; ERT, enzyme 
replacement therapy. 
Annualized rates of change from baseline in eGFRCKD-EPI by baseline 
renal function are provided in Table 3 (simple linear regression) and 
Table 1 
Baseline characteristics.  
Variable Overall (N =
78) 
ERT-naive patients ERT-experienced 
patients (n = 42) 
Males (n = 31) Females (n =
47) 
All (n = 36) Classic phenotypea 
(n = 10) 
Other (n = 26) 
Age (years)        
Mean (SD) 47.8 (12.6) 45.1 (10.5) 45.6 (12.0) 44.9 (10.2) 50.1 (13.8) 48.7 (12.2) 47.2 (12.9) 
Median (range) 48.0 (18–70) 45.5 (25–68) 45.0 (25–62) 46.0 (27–68) 53.5 (18–70) 48.0 (20–67) 48.0 (18–70) 
Sex, n (%)        
Male 19 (24.4) 13 (36.1) 10 (100) 2 (11.5) 18 (42.9) 31 (100) 0 
Female 59 (75.6) 23 (63.9) 0 23 (88.5) 24 (57.1) 0 47 (100%) 
Race, n(%)        
White 70 (89.7) 34 (94.4) 9 (90.0) 25 (96.2) 36 (85.7) 27 (87.1) 43 (91.5) 
Asian 5 (6.4) 0 0 0 5 (11.9) 3 (9.7) 2 (4.3) 
Multiple 1 (1.3) 0 0 0 1 (2.4) 0 1 (2.1) 
Other 2 (2.6) 2 (5.6) 1 (10.0) 1 (2.8) 0 1 (3.2) 1 (3.2) 
eGFRCKD-EPI (mL/min/ 
1.73 m2)        
Mean (SD) 90.2 (21.0) 91.4 (22.4) 86.4 (27.5) 93.3 (20.4) 89.2 (19.9) 85.8 (22.1) 93.1 (19.9) 




94.8 (41.4–119.0) 92.0 
(44.6–125.6) 




eGFRCKD-EPI category, n 
(%)        
>30–<60 mL/min/ 
1.73 m2 
5 (6.4) 3 (8.3) 2 (20.0) 1 (3.8) 2 (4.8) 4 (12.9) 1 (2.1) 
60–90 mL/min/1.73 
m2 
33 (42.3) 14 (38.9) 3 (30.0) 11 (42.3) 19 (45.2) 15 (48.4) 18 (38.3) 
>90 mL/min/1.73 m2 40 (51.3) 19 (52.8) 5 (50.0) 14 (53.8) 21 (50.0) 12 (38.7) 28 (59.6) 
Urinary protein, mg/24 h, 
n (%)        
<300 mg/24 h 54 (69.2) 22 (61.1) 4(40.0) 18 (69.2) 32 (76.2) 18 (58.1) 36 (76.6) 
300–1000 mg/24 h 18 (23.1) 10 (27.8) 4 (40.0) 6 (23.1) 8 (19.0) 9 (29.0) 9 (19.1) 
>1000 mg/24 h 6 (7.7) 4 (11.1) 2 (20.0) 2 (7.7) 2 (4.8) 4 (12.9) 2 (4.3) 
Patients taking ACEI/ 
ARB/RI, n (%) 
32 (41.0) 10 (27.8) 4 (40.0) 6 (23.1) 22 (52.4) 13 (41.9) 19 (40.4) 
Time since diagnosis 
(years)        
Mean (SD) 10.2 (10.9) 7.4 (8.0) 6.5 (4.4) 7.8 (9.1) 12.6 (12.4) 7.9 (8.6) 11.8 (11.9) 
Median (range) 5.5 (1.0, 44.0) 5.0 (1.0, 34.0) 6.0 (1–14) 5.0 (1–34) 6.0 (3.0, 44.0) 5.0 (1.0, 39.0) 6.0 (1.0, 44.0) 
LVMi (g/m2)        
Mean (SD) 95.7 (30.3) 99.2 (35.3) 120.5 (24.8) 89.9 (35.5) 92.9 (25.8) 116.4b (35.3) 82.4 (16.3)b 




115.4 (89.6–176.2) 81.2 
(61.0–234.4) 




α-Gal A, alpha galactosidase; ACEI, angiotension-converting enyzme inhibitor; ARB, angiotension II receptor blockers; eGFRCKD-EPI, estimated glomerular filtration rate 
using the Chronic Kidney Disease Epidemiology Collaboration equation; ERT,enzyme replacement therapy; LVMi, left ventricular mass index; RI, renin inhibitor; SD, 
standard deviation. 
a ERT-naive male patients who had residual white blood cell α-Gal A activity of <3% of normal and multiorgan system involvement, defined as involvement of ≥2 of 
the following organ systems: renal, cardiac, central nervous system, peripheral nerves, and gastrointestinal tract [21]. 
b LVMi data were not available for 2 male patients and 2 female patients. 
Table 2 
Annualized rate of change in eGFRCKD-EPI in ERT-naive and ERT-experienced 
patients treated with migalastat for ≥2 years using simple linear regression.   
ERT-naive patients ERT-experienced patients 
Overall Male Female Overall Male Female 




































eGFRCKD-EPI, estimated glomerular filtration rate using the Chronic Kidney 
Disease Epidemiology Collaboration equation; ERT, enzyme replacement ther-
apy; SD, standard deviation; Q1, quartile 1; Q3, quartile 3. 
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Fig. 2. Estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation over time in (A) male and (B) female patients 
receiving long-term migalastat treatment. 
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Table A.3 (random coefficient model); Fig. A.1B shows individual pa-
tient data. We analyzed the influence of each covariate included in the 
analysis and found that baseline eGFR was significant in predicting 
further decline in renal function (p < 0.0001), followed by age (p =
0.046). Baseline urine protein was approaching statistical significance 
(p = 0.059). Other covariates were not significant. 
Annualized change in eGFRCKD-EPI up to 24 months has been reported 
for 16 male patients with the classic phenotype in FACETS [21]. Among 
them, 10 patients had received migalastat for ≥2 years and were 
included in the current post hoc analysis. The mean (SD) annualized 
rates of change in eGFRCKD-EPI were − 1.7 (3.0) mL/min/1.73 m2 in this 
subset of male patients with the classic phenotype and − 1.5 (3.2) mL/ 
min/1.73 m2 in other patients in FACETS (simple regression) during 
long-term follow-up (Table 4). Using the random coefficient model, the 
mean (SD) annualized rates of change in eGFRCKD-EPI were − 0.5 (2.1) 
mL/min/1.73 m2 in ERT-naive males with the classic phenotype and 0.0 
(1.7) mL/min/1.73 m2 in other patients in FACETS, respectively 
(Table A.4). Annualized rate of change in eGFRCKD-EPI in male patients 
with multiorgan involvement versus others have been similarly 
analyzed for ERT-experienced patients (Table A4 and Table A.4) The 
genotype, phenotype, and annualized rate of change in eGFRCKD-EPI of 
individual patients are presented in Table A.5. Multiorgan involvement 
for patients is listed in Table A.6. Individual eGFRCKD-EPI slopes are 
plotted against patient age in Fig. A.2. 
4. Discussion 
This post hoc analysis assessed long-term renal measures associated 
with migalastat therapy in ERT-naive and ERT-experienced patients 
with Fabry disease and amenable GLA variants. With either the random 
coefficient model or simple linear regression, ERT-naive and ERT- 
experienced patients who received migalastat treatment for ≥2 and ≤
8.6 years in the current study had a rate of eGFR decline that was slower 
than that in untreated historical cohorts [22,23] and similar to the 
normal rate of decline with age [24]. Renal function was also generally 
stable in patients receiving long-term migalastat treatment irrespective 
of treatment status, sex, or phenotype. 
Although linear regression models have often been used to estimate 
rates of change in eGFR over time, this statistical method fails to 
consider the correlation among repeated measurements in the same 
patient. A subject-specfic mixed model with random intercepts and 
slopes for each patient may be more suitable to the heterogeneous na-
ture of Fabry disease and has been used to describe the natural history of 
Fabry nephropathy [22], which showed that untreated males and fe-
males (mean age 41 years at baseline) with a baseline eGFRMDRD of ≥60 
mL/min/1.73 m2 experienced an annual loss in eGFR of − 3.0 mL/min/ 
1.73 m2 and − 0.9 mL/min/1.73 m2, respectively; males and females 
with chronic kidney disease at baseline experienced an annual loss in 
eGFR of − 6.8 mL/min/1.73 m2 and − 2.1 mL/min/1.73 m2, respectively 
[22]. Using a similar model, we found that eGFRCKD-EPI remained stable 
during median follow-ups of 7 years and 5 years in ERT-naive and ERT- 
experienced patients, respectively (mean annualized rate of change was 
− 0.1 mL/min/1.73 m2 and 0.1 mL/min/1.73 m2, respectively). 
A range of mean eGFR declines has been reported for ERT using 
different statistical methods [25–28]. In a 5-year follow-up of adult 
patients treated with agalsidase alfa or agalsidase beta, the mean 
annualized rates of change in eGFR were approximately − 3 mL/min/ 
1.73 m2 in males (mean age 38.9 years, mean baseline eGFR 88.5 mL/ 
min/1.73 m2) and approximately − 0.9 mL/min/1.73 m2 in females 
(mean age 46.8 years, mean eGFR 86.6 mL/min/1.73 m2) using a 
random coefficient model [25]. In another long-term study of patients 
(median age 33 years) receiving agalsidase alfa or agalsidase beta for a 
median of 7 years, the mean annualized rates of change in eGFR were −
1.8 mL/min/1.73 m2 and − 0.01 mL/min/1.73 m2 in males (mean 
baseline eGFR 121 mL/min/1.73 m2) and females (mean baseline eGFR 
98 mL/min/1.73 m2), respectively, using a linear mixed model [29]. 
These rates of eGFR decline during ERT are generally similar to or 
greater than those reported here for migalastat. 
It is known that baseline clinical status plays a critical role in renal 
outcomes with treatment [25–27]. In long-term studies, ERT did not 
stabilize renal function in patients with severe renal involvement (ie, 
Table 3 
Annualized rates of change in eGFRCKD-EPI in ERT-naive and ERT-experienced patients treated with migalastat for ≥2 years by baseline renal function using simple 
linear regression.   
ERT-naive patients ERT-experienced patients 
n = 36 n = 42 
Baseline eGFRCKD-EPI, mL/min/1.73 m2 >90 60–90 >30–<60 >90 60–90 >30–<60 
(n = 19) (n = 14) (n = 3) (n = 21) (n = 19) (n = 2) 
Mean (SD) − 2.2 (2.9) − 0.81 (2.9) − 1.2 (5.1) − 1.2 (1.5) − 1.6 (5.0) − 4.7 (2.1) 
Median (Q1, Q3) − 1.0  
(− 2.3, − 0.7) 
− 1.1  
(− 2.6, 0.1) 
− 1.2  
(− 6.3, 4.0) 
− 1.3  
(− 2.0, − 0.8) 
− 0.9  
(− 2.2, − 0.2) 
− 4.7  
(− 6.2, − 3.2)  
Baseline urinary protein, mg/24 h <300 (n = 22) 300–1000 (n = 10) >1000 (n = 4) <300 (n = 32) 300–1000 (n = 8) >1000 (n = 2) 
Mean (SD) − 2.0 (3.0) − 0.1 (3.1) − 2.9 (2.6) − 0.8 (1.9) − 1.9 (0.8) − 13.3 (10.1) 
Median (Q1, Q3) − 1.1 (− 2.3, − 0.7) − 0.8 (− 1.7, 0.0) − 2.3  
(− 5.0, − 0.8) 
− 1.0 (− 1.7, − 0.3) − 1.7 (− 2.6, − 1.3) − 13.3  
(− 20.5, − 6.2) 
eGFRCKD-EPI, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation; ERT, enzyme replacement therapy; Q1, 
quartile 1; Q3, quartile 3; SD, standard deviation. 
Table 4 
Annualized rates of change in eGFRCKD-EPI in ERT-naive and ERT-experienced 
patients treated with migalastat for ≥2 years by disease characteristics using 
simple linear regression.   






(n = 10) (n = 26) (n = 15) (n = 27) 
Mean (SD) − 1.7 (3.0) − 1.5 (3.2) − 2.5 (5.1) − 1.1 (2.3) 
Median 
(Q1, Q3) 
− 0.9 (− 4.0, 
0.1) 
− 1.1 (− 2.3, 
− 0.7) 
− 1.3 (− 2.6, − 0.4) − 1.3 (− 2.2, 
− 0.5) 
α-Gal A, alpha galactosidase; eGFRCKD-EPI, estimated glomerular filtration rate 
using the Chronic Kidney Disease Epidemiology Collaboration equation; ERT, 
enzyme replacement therapy; Q1, quartile 1; Q3, quartile 3; SD, standard 
deviation. 
a ERT-naive male patients with the classic phenotype had residual white blood 
cell α-Gal A activity of <3% of normal and multiorgan involvement, defined as 
involvement of ≥2 of the following organ systems: renal, cardiac, central ner-
vous system, peripheral nerves, and gastrointestinal tract [21]. 
b Baseline white blood cell α-Gal A activity in ERT-experienced patients was 
confounded by ERT and the same classic phenotype definition could not be 
applied. Instead, male patients with multiorgan involvement were compared 
with males without multiorgan involvement and females (specified above as 
“others”). 
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proteinuria >1 g/24 h or eGFR <60 mL/min/1.73 m2, or urinary pro-
tein:creatinine ratio ≥ 1 g/g) [30–32]. In our study, renal outcomes 
were similar across baseline renal function groups in ERT-naive patients 
with the random coefficient model that adjusted for baseline factors. 
Unsurprisingly, with the simple linear regression method, larger annu-
alized rates of change in eGFR were observed in ERT-experienced pa-
tients with low eGFR (> 30 to <60 mL/min/1.73 m2) or high urine 
protein (> 1000 mg/24 h) at baseline in the current study compared 
with other analyzed subgroups. However, our results are severely 
limited by the small sample sizes of these 2 patient subgroups (n = 2 
each). Results were also distorted by one patient with an eGFR decline of 
>20 mL/min/1.73 m2; however, it is likely that this patient had irre-
versible nephropathy prior to migalastat initiation. as evidenced by the 
large decline in renal function that also occurred during ERT treatment. 
Long-term data are especially important when assessing annualized 
change in eGFR. A recent Delphi consensus has recommended at least 2 
years of data for reliable eGFR analyses [33], and the current analysis 
provides data on patients who were treated with migalastat for at least 2 
years (median exposure 5.9 years). Published real-world evidence can 
also be helpful in guiding treatment decisions. A recent 24-month real- 
world cohort publication from Lenders et al. in Germany provided 
further evidence of LVMi reduction in migalastat-treated patients with 
Fabry disease (primary outcome), especially in those with left ven-
tricualr hypertrophy at baseline [34]. That publication also examined 
annualized eGFR slopes over 24 months and found antihypertensive 
medication use was associated with greater annualized eGFR decline 
over time, and the authors posited that either this may have been 
causative of the larger decline in eGFR, or that these patients were more 
severely affected at baseline. When excluding the patients on inhibitors 
of angiotensin-converting enzyme, angiotensin II receptor 1, or aldo-
sterone, eGFR was found to be stable over 24 months in migalastat- 
treated patients (mean change over 24 months: − 3.0 ± 10.9 mL/min/ 
1.73 m2; p = 0.4346). These findings support the thinking that patient 
management decisions should be made holistically, and that treatment 
before irreversible damage has occurred may be beneficial. 
The current study also extends findings from a previous analysis of 
male patients with the classic phenotype in the FACETS study [21], 
which reported a mean annualized rate of change in eGFRCKD-EPI of − 0.3 
mL/min/1.73 m2 over 2 years. The current study shows that renal 
function remained stable in ERT-naive male patients with the classic 
phenotype for ≤8.6 years (median exposure: 6.6 years), supporting long- 
term efficacy in this patient population. In comparison, male patients 
with the classic phenotype (mean age 31 years, median baseline eGFR 
~120 mL/min/1.73 m2) who received agalsidase beta for 54 months 
had an eGFR decline of − 2.2 mL/min/1.73 m2, as estimated by a 
random coefficient model [21,30]. The current study also included male 
patients with the classic phenotype who had relatively high eGFR values 
at baseline (mean [SD]: 88.5 [22.5] mL/min/1.73 m2). Interestingly, 
one patient with the classic phenotype in our study had a GLA variant 
associated with the late-onset phenotype (p.I253T) according to the 
International Fabry Disease Genotype-Phenotype Database, which con-
solidates data in the literature as well as available biochemical data to 
set a reasonable expectation of phenotypic severity [35], This supports 
the thinking that that genotype-phenotype correlation is complex and 
that environmental factors and genetic modifiers may be at work. This 
observation highlights the importance of evaluating each patient holis-
tically, and of making individualized treatment decisions that account 
for the multiple organ systems affected by Fabry disease. It also high-
lights the fact that the GLP-HEK amenability assay should be used only 
to determine a patient's eligibility for treatment with migalastat and that 
the assay is not prognostic of clinical outcomes or disease course. 
Finally, some patients with the same variant had different severity of 
disease at study baseline, possibly related to entering the study at 
different stages during the progressive disease course [1], which high-
lights the importance of multisystemic monitoring and early treatment 
initiation when managing this disease. 
There is a growing consensus that treatment should be initiated early 
to limit or prevent irreversible organ damage and improve treatment 
outcomes in patients with Fabry disease [31,37,38]. In this study, we 
defined the classic phenotype as multiorgan system involvement at 
baseline, and < 3% enzyme activity for male patients (ERT-naive only). 
We used this phenotypic definition in accordance with the definition 
used in the FACETS trial [15,21] in order to analyze patients with 
clinically advanced Fabry disease at study start. Fabry disease pheno-
types and rates of disease progression are highly variable, even within 
families with the same variant [39]. A binary definition of “classic” 
versus “other” does not capture the true complexity of Fabry disease. We 
posit that Fabry disease is a continuum, dependent upon many factors, 
including genetic, epigenetic, environmental, and lifestyle, and that 
such binary classifications should be considered as only one factor in 
terms of guiding treatment decisions. Biopsy studies suggest that 
podocyte injury occurs in early childhood, progresses with increasing 
age, and may act as an early marker for renal damage in Fabry disease 
[40–42]. Therefore, treatment before substantial renal damage occurs is 
imperative because renal function may not be restored when podocyte 
loss and damage to glomeruli have occurred [43,44]. There is also evi-
dence of a strong correlation between proteinuria and renal disease 
progression in patients with Fabry disease [45]. Therefore, stabilizing or 
slowing the decline in renal function requires strategies that control 
proteinuria (ie, angiotensin-converting-enzyme inhibitors and/or 
angiotensin II receptor blockers) [46].Furthermore, inflammatory pro-
cesses in podocytes have been linked to Fabry nephropathy, suggesting 
inflammatory pathways could potentially be therapeutic targets in Fabry 
disease [4]. Further studies are needed to investigate the impact of 
current therapies, including migalastat, on these pathophysiological 
processes in renal tissues and optimal time for treatment initiation. 
Limitations of this study that should be considered when interpreting 
the results include its post hoc design, small sample sizes in some sub-
groups, and the lack of statistical comparisons with untreated or ERT- 
treated historical cohorts. Assessment of renal function using eGFR 
may also be a limitation, given that eGFR has been associated with 
pseudo-hyperfiltration in some patients with Fabry disease [36]. In 
addition, the heterogeneity of statistical methods used to estimate eGFR 
slopes in the literature limited direct comparisons. 
In summary, the results of this post hoc analysis suggest that patients 
with Fabry disease and amenable GLA variants had stable renal function 
during long-term migalastat treatment (≤8.6 years) irrespective of 
treatment status, sex or phenotype. Early treatment should be encour-
aged to stabilize or slow the decline in renal function in patients with 
Fabry disease. 
Data availability statement 
All relevant data, including deidentified participant data, are con-
tained in this manuscript and its supplemental materials. 
Author contributions 
D.G.B., R.T., D.H., R.G., N.S., U.F.R. and K.N. contributed to 
conceptualization; D.H., N.S., U.F.R. and K.N., participated in data 
curation; R.T., D.H., R.G., N.S., U.F.R. and K.N. participated in investi-
gation; R.T., R.G., N.S., E.K., U.F.R. and K.N. contributed to methodol-
ogy; D.G.B. and D.H. participated in supervision; R.T. and D.H. 
contributed to validation; R.T. and E.W. contributed to visualization; N. 
S. and E.K. analyzed and interpreted the data; R.T. participated in 
writing the original draft; D.G.B., R.T., E.W., D.H., R.G., N.S., E.K., U.F. 
R., R.S. and K.N. participated in reviewing and editing the article. 
Funding 
This study was funded by Amicus Therapeutics, Inc. 
D.G. Bichet et al.                                                                                                                                                                                                                                
Molecular Genetics and Metabolism Reports 28 (2021) 100786
8
Declaration of Competing Interest 
D.G.B. served as a consultant and speaker for and received grants 
from Amicus, Sanofi Genzyme and Otsuka; and served as a board 
member for Amicus. 
E.W. received grants and consulting fees from Sanofi Genzyme and 
received research and travel support from Protalix and Idorsia. 
D.H. received consultant fees from Amicus, Sanofi Genzyme, Shire- 
Takeda, Protalix, Idorisia, and Freeline Therapeutics; and served as a 
speaker for Amicus, Shire-Takeda, and Sanofi Genzyme. 
R.G. was a paid consultant for JCR Pharmaceuticals, REGENXBIO, 
and Sigilon; received grants from BioMarin, Novartis, Shire-Takeda, and 
Ultragenyx; was a paid speaker for Amicus, BioMarin, Chiesi, Janssen, 
PTC Therapeutics, Sanofi Genzyme, Shire-Takeda, and Ultragenyx; and 
served as a board member for Amicus, Abeona, Sobi, Sanofi Genzyme, 
and Shire-Takeda. 
N.S. was an employee of Amicus at the time of this study. 
E.K. served as a paid consultant for Amicus. 
U.F.R. served as a board member and paid consultant for Amicus, 
Sanofi Genzyme, and Shire-Takeda, and received an unrestricted 
research grant from Sanofi Genzyme. 
K.N. has served on advisory boards for Amicus Therapeutics, Sanofi 
Genzyme, and Shire; has served as a speaker for Amicus Therapeutics; 
and has received research funding from Sanofi Genzyme and Shire. 
R.T. and R.S have no conflicts to declare. 
Acknowledgments 
This study was funded by Amicus Therapeutics, Inc. The authors 
thank the patients and their families, as well as the FACETS and 
ATTRACT study investigators. Third-party medical writing assistance 
was provided by Stephanie Agbu, PhD, and Lei Bai, PhD (ApotheCom, 
Yardley, PA, USA), and was supported by Amicus Therapeutics, Inc. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ymgmr.2021.100786. 
References 
[1] D.P. Germain, Fabry disease, Orphanet J. Rare Dis. 5 (2010) 30. 
[2] R.J. Desnick, Y. Ioannou, C.M. Eng, a-Galactosidase a deficiency: Fabry disease, in: 
D. Valle (Ed.), The Online Metabolic and Molecular Bases of Inherited Disease, 
McGraw-Hill Companies, Inc., 2016. 
[3] J. Alroy, S. Sabnis, J.B. Kopp, Renal pathology in Fabry disease, J. Am. Soc. 
Nephrol. 13 (Suppl. 2) (2002) S134–S138. 
[4] M.D. Sanchez-Nino, A.B. Sanz, S. Carrasco, M.A. Saleem, P.W. Mathieson, J. 
M. Valdivielso, et al., Globotriaosylsphingosine actions on human glomerular 
podocytes: implications for Fabry nephropathy, Nephrol. Dial. Transplant. 26 
(2011) 1797–1802. 
[5] P.A. Rozenfeld, M. de Los Angeles Bolla, P. Quieto, A. Pisani, S. Feriozzi, 
P. Neuman, et al., Pathogenesis of Fabry nephropathy: the pathways leading to 
fibrosis, Mol. Genet. Metab. 129 (2020) 132–141. 
[6] A. Mehta, J.T. Clarke, R. Giugliani, P. Elliott, A. Linhart, M. Beck, et al., Natural 
course of Fabry disease: changing pattern of causes of death in FOS - Fabry 
Outcome Survey, J. Med. Genet. 46 (2009) 548–552. 
[7] S. Waldek, M.R. Patel, M. Banikazemi, R. Lemay, P. Lee, Life expectancy and cause 
of death in males and females with Fabry disease: findings from the Fabry registry, 
Genet. Med. 11 (2009) 790–796. 
[8] A. Ortiz, B. Cianciaruso, M. Cizmarik, D.P. Germain, R. Mignani, J.P. Oliveira, et 
al., End-stage renal disease in patients with Fabry disease: natural history data from 
the Fabry registry, Nephrol. Dial. Transplant. 25 (2010) 769–775. 
[9] A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C.Y. Hsu, Chronic kidney disease 
and the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med. 
351 (2004) 1296–1305. 
[10] Fabrazyme (Agalsidese Beta) Injection, Powder, lyophilized for Solution for 
Intravenous Use. Prescribing Information, Genzyme Corporation, 2010. 
[11] Replagal 1 mg/ml Concentrate for Solution for Infusion. Summary of Product 
Characteristics, Shire Pharmaceuticals Limited, 2016. 
[12] Galafold (migalastat) capsules, for oral use. Prescribing information, Amicus 
Therapeutics Inc., 2019. 
[13] G.H. Yam, C. Zuber, J. Roth, A synthetic chaperone corrects the trafficking defect 
and disease phenotype in a protein misfolding disorder, FASEB J. 19 (2005) 12–18. 
[14] S. Ishii, H.H. Chang, K. Kawasaki, K. Yasuda, H.L. Wu, S.C. Garman, et al., Mutant 
alpha-galactosidase a enzymes identified in Fabry disease patients with residual 
enzyme activity: biochemical characterization and restoration of normal 
intracellular processing by 1-deoxygalactonojirimycin, Biochem. J. 406 (2007) 
285–295. 
[15] D.P. Germain, D.A. Hughes, K. Nicholls, D.G. Bichet, R. Giugliani, W.R. Wilcox, et 
al., Treatment of Fabry's disease with the pharmacologic chaperone migalastat, 
N. Engl. J. Med. 375 (2016) 545–555. 
[16] D.A. Hughes, K. Nicholls, S.P. Shankar, G. Sunder-Plassmann, D. Koeller, K. Nedd, 
et al., Oral pharmacological chaperone migalastat compared with enzyme 
replacement therapy in Fabry disease: 18-month results from the randomised phase 
III ATTRACT study, J. Med. Genet. 54 (2017) 288–296. 
[17] M. Mauer, A. Sokolovskiy, J.A. Barth, J.P. Castelli, H.N. Williams, E.R. Benjamin, et 
al., Reduction of podocyte globotriaosylceramide content in adult male patients 
with Fabry disease with amenable GLA mutations following 6 months of migalastat 
treatment, J. Med. Genet. 54 (2017) 781–786. 
[18] E.R. Benjamin, M.C. Della Valle, X. Wu, E. Katz, F. Pruthi, S. Bond, et al., The 
validation of pharmacogenetics for the identification of Fabry patients to be treated 
with migalastat, Genet. Med. 19 (2017) 430–438. 
[19] A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro III, H.I. Feldman, et 
al., A new equation to estimate glomerular filtration rate, Ann. Intern. Med. 150 
(2009) 604–612. 
[20] L.M. Sullivan, K.A. Dukes, E. Losina, Tutorial in biostatistics. An introduction to 
hierarchical linear modelling, Stat. Med. 18 (1999) 855–888. 
[21] D.P. Germain, K. Nicholls, R. Giugliani, D.G. Bichet, D.A. Hughes, L.M. Barisoni, et 
al., Efficacy of the pharmacologic chaperone migalastat in a subset of male patients 
with the classic phenotype of Fabry disease and migalastat-amenable variants: data 
from the phase 3 randomized, multicenter, double-blind clinical trial and extension 
study, Genet. Med. 21 (2019) 1987–1997. 
[22] R. Schiffmann, D.G. Warnock, M. Banikazemi, J. Bultas, G.E. Linthorst, 
S. Packman, et al., Fabry disease: progression of nephropathy, and prevalence of 
cardiac and cerebrovascular events before enzyme replacement therapy, Nephrol. 
Dial. Transplant. 24 (2009) 2102–2111. 
[23] M. Branton, R. Schiffmann, J.B. Kopp, Natural history and treatment of renal 
involvement in Fabry disease, J. Am. Soc. Nephrol. 13 (Suppl. 2) (2002) 
S139–S143. 
[24] M. Baba, T. Shimbo, M. Horio, M. Ando, Y. Yasuda, Y. Komatsu, et al., Longitudinal 
study of the decline in renal function in healthy subjects, PLoS One 10 (2015), 
e0129036. 
[25] S.M. Rombach, B.E. Smid, M.G. Bouwman, G.E. Linthorst, M.G. Dijkgraaf, C. 
E. Hollak, Long term enzyme replacement therapy for Fabry disease: effectiveness 
on kidney, heart and brain, Orphanet J. Rare Dis. 8 (2013) 47. 
[26] A. Mehta, M. Beck, P. Elliott, R. Giugliani, A. Linhart, G. Sunder-Plassmann, et al., 
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: 
an analysis of registry data, Lancet. 374 (2009) 1986–1996. 
[27] M. Beck, D. Hughes, C. Kampmann, S. Larroque, A. Mehta, G. Pintos-Morell, et al., 
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a 
Fabry outcome survey analysis, Mol. Genet. Metab. Rep. 3 (2015) 21–27. 
[28] D.P. Germain, J. Charrow, R.J. Desnick, N. Guffon, J. Kempf, R.H. Lachmann, et al., 
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients 
with Fabry disease, J. Med. Genet. 52 (2015) 353–358. 
[29] C.V. Madsen, H. Granqvist, J.H. Petersen, A.K. Rasmussen, A.M. Lund, P. Oturai, et 
al., Age-related renal function decline in Fabry disease patients on enzyme 
replacement therapy: a longitudinal cohort study, Nephrol. Dial. Transplant. 34 
(2018) 1525–1533. 
[30] D.P. Germain, S. Waldek, M. Banikazemi, D.A. Bushinsky, J. Charrow, R.J. Desnick, 
et al., Sustained, long-term renal stabilization after 54 months of agalsidase beta 
therapy in patients with Fabry disease, J. Am. Soc. Nephrol. 18 (2007) 1547–1557. 
[31] D.G. Warnock, A. Ortiz, M. Mauer, G.E. Linthorst, J.P. Oliveira, A.L. Serra, et al., 
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria 
and timing of treatment initiation, Nephrol. Dial. Transplant. 27 (2012) 
1042–1049. 
[32] M. Banikazemi, J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, M. McDonald, et 
al., Agalsidase-beta therapy for advanced Fabry disease: a randomized trial, Ann. 
Intern. Med. 146 (2007) 77–86. 
[33] D. Moreno-Martinez, P. Aguiar, C. Auray-Blais, M. Beck, D.G. Bichet, A. Burlina, et 
al., Standardising clinical outcomes measures for adult clinical trials in Fabry 
disease: a global Delphi consensus, Mol. Genet. Metab. 132 (2021) 234–243. 
[34] M. Lenders, P. Nordbeck, C. Kurschat, M. Eveslage, N. Karabul, J. Kaufeld, et al., 
Treatment of Fabry disease with migalastat-outcome from a prospective 24 months 
observational multicenter study (FAMOUS), Eur. Heart J. Cardiovasc. 
Pharmacother (2021), https://doi.org/10.1093/ehjcvp/pvab025. 
[35] I.S.o.M.a.M. Sinai, International Fabry Disease Genotype-Phenotype Database 
(dbFGP), Icahn School of Medicine at Mount Sinai, New York, NY, 2016. Updated 
2016, http://dbfgp.org/dbFgp/fabry/Mutation.html. 
[36] E. Riccio, M. Sabbatini, D. Bruzzese, L. Annicchiarico Petruzzelli, A. Pellegrino, 
L. Spinelli, et al., Glomerular hyperfiltration: an early marker of nephropathy in 
Fabry disease, Nephron. 141 (2019) 10–17. 
[37] R.J. Hopkin, J.L. Jefferies, D.A. Laney, V.H. Lawson, M. Mauer, M.R. Taylor, et al., 
The management and treatment of children with Fabry disease: a United States- 
based perspective, Mol. Genet. Metab. 117 (2016) 104–113. 
[38] M. Biegstraaten, R. Arngrimsson, F. Barbey, L. Boks, F. Cecchi, P.B. Deegan, et al., 
Recommendations for initiation and cessation of enzyme replacement therapy in 
D.G. Bichet et al.                                                                                                                                                                                                                                
Molecular Genetics and Metabolism Reports 28 (2021) 100786
9
patients with Fabry disease: the European Fabry working group consensus 
document, Orphanet J. Rare Dis. 10 (2015) 36. 
[39] M. Rigoldi, D. Concolino, A. Morrone, F. Pieruzzi, R. Ravaglia, F. Furlan, et al., 
Intrafamilial phenotypic variability in four families with Anderson-Fabry disease, 
Clin. Genet. 86 (2014) 258–263. 
[40] M. Liern, A. Collazo, M. Valencia, A. Fainboin, L. Isse, C. Costales-Collaguazo, et 
al., Podocyturia in paediatric patients with Fabry disease, Nefrologia. 39 (2019) 
177–183. 
[41] C. Tondel, T. Kanai, K.K. Larsen, S. Ito, J.M. Politei, D.G. Warnock, et al., Foot 
process effacement is an early marker of nephropathy in young classic Fabry 
patients without albuminuria, Nephron. 129 (2015) 16–21. 
[42] B. Najafian, E. Svarstad, L. Bostad, M.C. Gubler, C. Tondel, C. Whitley, et al., 
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in 
young patients with Fabry disease, Kidney Int. 79 (2011) 663–670. 
[43] W.R. Wilcox, M. Banikazemi, N. Guffon, S. Waldek, P. Lee, G.E. Linthorst, et al., 
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease, 
Am. J. Hum. Genet. 75 (2004) 65–74. 
[44] B. Najafian, C. Tøndel, E. Svarstad, M.C. Gubler, J.P. Oliveira, M. Mauer, 
Accumulation of Globotriaosylceramide in podocytes in Fabry nephropathy is 
associated with progressive podocyte loss, J. Am. Soc. Nephrol. 31 (2020) 
865–875. 
[45] C. Wanner, J.P. Oliveira, A. Ortiz, M. Mauer, D.P. Germain, G.E. Linthorst, et al., 
Prognostic indicators of renal disease progression in adults with Fabry disease: 
natural history data from the Fabry registry, Clin. J. Am. Soc. Nephrol. 5 (2010) 
2220–2228. 
[46] A. Ortiz, J.P. Oliveira, C. Wanner, B.M. Brenner, S. Waldek, D.G. Warnock, 
Recommendations and guidelines for the diagnosis and treatment of Fabry 
nephropathy in adults, Nat. Clin. Pract. Nephrol. 4 (2008) 327–336. 
D.G. Bichet et al.                                                                                                                                                                                                                                
